1. Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase
- Author
-
Sandra Strollo, Gianfranco Peluso, Caterina Porto, Gerlind Sulzenbacher, Carla Damiano, Nadia Minopoli, Antonietta Tarallo, Marco Moracci, Véronique Roig-Zamboni, Giancarlo Parenti, Beatrice Cobucci-Ponzano, Maria Carmina Ferrara, Roberta Iacono, Department of Biology, University of Naples 'Federico II', Architecture et fonction des macromolécules biologiques (AFMB), Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and University of Naples Federico II = Università degli studi di Napoli Federico II
- Subjects
glycogen storage disease type 2 ,[SDV]Life Sciences [q-bio] ,Allosteric regulation ,RM1-950 ,Pharmacology ,alpha-Glucosidase ,03 medical and health sciences ,Structure-Activity Relationship ,0302 clinical medicine ,Allosteric Regulation ,Carnitine ,Drug Discovery ,medicine ,Humans ,Glycoside Hydrolase Inhibitors ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,biology ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,carbohydrate active enzymes ,Metabolic disorder ,lysosomal disease ,alpha-Glucosidases ,General Medicine ,Enzyme replacement therapy ,medicine.disease ,Small molecule ,3. Good health ,Pharmacological chaperone ,Enzyme ,α-Glucosidase ,orphan drugs ,Chaperone (protein) ,biology.protein ,Therapeutics. Pharmacology ,Lysosomes ,030217 neurology & neurosurgery ,medicine.drug ,Research Article ,Research Paper ,Molecular Chaperones - Abstract
International audience; Pompe disease is an inherited metabolic disorder due to the deficiency of the lysosomal acid α-glucosidase (GAA). The only approved treatment is enzyme replacement therapy with the recombinant enzyme (rhGAA). Further approaches like pharmacological chaperone therapy, based on the stabilising effect induced by small molecules on the target enzyme, could be a promising strategy. However, most known chaperones could be limited by their potential inhibitory effects on patient's enzymes. Here we report on the discovery of novel chaperones for rhGAA, L- and D-carnitine, and the related compound acetyl-D-carnitine. These drugs stabilise the enzyme at pH and temperature without inhibiting the activity and acted synergistically with active-site directed pharmacological chaperones. Remarkably, they enhanced by 4-fold the acid α-glucosidase activity in fibroblasts from three Pompe patients with added rhGAA. This synergistic effect of L-carnitine and rhGAA has the potential to be translated into improved therapeutic efficacy of ERT in Pompe disease.
- Published
- 2021
- Full Text
- View/download PDF